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Abstract
Background: Toxoplasma gondii can infect almost all warm-blood animals including human beings. The plant-like
calcium-dependent protein kinases (CDPKs) harbored by T. gondii are involved in gliding motility, cell invasion,
egress and some other developmental processes, and so have been implicated as important virulence factors.
Methods: In the present study, we constructed a DNA vaccine expressing T. gondii CDPK3 (TgCDPK3) and evaluated its
protective efficacy against T. gondii infection in Kunming mice. The gene sequence encoding TgCDPK3 was inserted into
the eukaryotic expression vector pVAX I, and mice were immunized with pVAX-CDPK3 intramuscularly.
Results: The results showed that mice immunized with pVAX-CDPK3 developed a high level of specific antibodies and a
strong lymphoproliferative response. The significantly increased levels of IFN-γ, IL-2, IL-12 (p70) and IL-23 and high ratio of
IgG2a to IgG1 antibody titers indicated that a Th1 type response was elicited after immunization with pVAX-CDPK3.
Furthermore, the percentage of CD4+ T cells in mice vaccinated with pVAX-CDPK3 was significantly increased. After lethal
challenge with the tachyzoites of the virulent T. gondii RH strain, the mice immunized with pVAX-CDPK3 prolonged the
survival time from 10 days to 24 days (13.5 ± 4.89) compared to untreated mice or those received PBS or pVAX I which died
within 7 days (P< 0.05). In chronic infection model (10 cysts of the T. gondii PRU strain), the numbers of brain cysts of the
mice immunized with pVAX-CDPK3 reduced significantly when compared with those in control groups (P < 0.05), and the
rate of reduction could reach to about 50%.
Conclusions: TgCDPK3 can generate protective immunity against acute and chronic T. gondii infection in Kunming mice
and is a promising vaccine candidate for further development of an effective vaccine against T. gondii.
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Background
Toxoplasma gondii, an obligate intracellular protozoan
parasite, is responsible for toxoplasmosis in a wide range of
hosts including humans, mammals, birds and marine
mammals [1-5]. T. gondii infection in immune-competent
individuals is rarely symptomatic, but toxoplasmosis oc-
curred in fetus and immunocompromised hosts may result
in severe disease or even lethal damage [5-7]. Meanwhile,
the infection can cause serious economic losses to the live-
stock industry, especially in sheep and goats, as the course
of abortion, stillbirth and neonatal loss [8], and also the in-
fected animals are major sources of T. gondii transmission
to humans [4,6].
No available chemical treatments could completely elim-
inate T. gondii in infected animals, so immunoprophylaxis
is considered to be high priority for prevention and control
of the parasite [9,10]. Although the only licensed vaccine
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based on the attenuated-live T. gondii S48 strain (Toxovax®)
can be used to prevent the incidence of abortion in sheep
[11], it is limited to be further explored in food-producing
animals or humans in view of the safety concerns on its
reverting to a virulence wild type. The current efforts
have been made on the development of DNA vaccines
due to the superiority of much safer than live-type vac-
cines, as well as their ability to induce primarily Th1
cell-mediated immune and CD8+ cytotoxic T cells
(CTL) responses [12,13].
A family of calcium-dependent protein kinases (CDPK)
is known as key effectors in regulating calcium related sig-
naling pathways in apicomplexan, which control a diverse
array of functions in the life cycle including gliding motil-
ity, cell invasion, egress and some other developmental
processes that occur at distinct stages in their complex life
[14]. TgCDPK3, a characteristic member of CDPKs, is lo-
calized to the parasite periphery in intracellular and extra-
cellular parasites and partially to the apical end of the
intracellular parasite [15]. The TgCDPK3 knockout strain
showed fewer parasites per vacuole than parental strains,
which implied that the gene can partially influence the
division of T. gondii [15]. However, no studies have evalu-
ated the immunogenicity of TgCDPK3 and its potential as
a vaccine candidate against T. gondii infection.
In this context, the objectives of the present study
were to examine the various immune responses in
mice induced by DNA immunization with a eukaryotic
plasmid expressing TgCDPK3, and to evaluate the
potential of TgCDPK3 as a vaccine candidate against




Specific-pathogen-free (SPF) female inbred Kunming
mice of 6–8 weeks old were purchased from Center of La-
boratory Animals, Lanzhou Institute of Biological Prod-
ucts, Lanzhou, China. All mice were handled in strict
accordance with the Good Animal Practice requirements
of the Animal Ethics Procedures and Guidelines of the
People’s Republic of China. This study was approved by
the Animal Ethics Committee of LanzhouVeterinary Re-
search Institute, Chinese Academy of Agricultural Sci-
ences (Approval No. LVRIAEC2012-011).
Parasites
T. gondii RH and PRU strains were used in this study.
Tachyzoites of the highly virulent T. gondii RH strain
(Type I) were propagated by serial intraperitoneal passage
in Kunming mice. The peritoneal fluid of mice was centri-
fuged for 10 min at 1 000 × g at 4°C to remove the cellular
debris and then re-suspended in sterile phosphate-
buffered saline (PBS). The obtained tachyzoites were also
used for Toxoplasma lysate antigen (TLA) preparation ac-
cording to our previous studies [16] and total RNA extrac-
tion was followed by the instruction of the RNAprep Pure
Tissue Kit (TIANGEN, China) manual. Cysts of the PRU
strain (Type II) were maintained in the laboratory by oral
passage of infective brain homogenate in Kunming mice.
Construction of the eukaryotic expression plasmid
The complete open reading frame (ORF) of TgCDPK3
was amplified by reverse transcription-polymerase chain
reaction (RT-PCR) using primers K3F (5′-GCGGGTAC
CATGGCGGATCCGCTCTCGTTCTTCAAC-3′) and K3R
(5′-GGGCGGCCGCTCACTCATGTTGCGACTCAC-3′),
in which the Kpn I and Not I restriction sites were
introduced and shown in italic, respectively. After puri-
fication using the TIANquick Midi Purification Kit
(TIANGEN, China), the PCR products were inserted
into pVAX I (Invitrogen) through Kpn I and Not I sites.
The resulting plasmid was named pVAX-CDPK3. The
concentration of extracted pVAX-CDPK3 was deter-
mined by spectrophotometry at OD260 and OD280.
The plasmids were diluted with sterile phosphate buff-
ered saline (PBS) to a final concentration of 1 μg/μl
and stored at −20°C.
Expression of pVAX-CDPK3 in vitro
Recombinant plasmid pVAX-CDPK3 was transfected
into HEK293 cells grown in 6-well plates using lipofecta-
mine 2000 reagent (Invitrogen) according to the manu-
facturer’s instructions. The expression of pVAX-CDPK3
in vitro was assayed by indirect immunofluorescence
assay (IFA) at 48 after transfection. The protocol of IFA
followed previous report [16]. Briefly, the transfected
cells were firstly fixed with 100% acetone and washed
with PBS-0.1% Triton-X-100 (PBST). Then goat anti-T.
gondii tachyzoites polyclonal antibody (1: 50 dilution in
PBST) and fluorescein isothiocyanate (FITC) labeled
rabbit anti-goat mouse IgG antibody (1:2 000, Sigma,
USA) were added into each well in proper order. As
a negative control, the HEK293 cells were transfected
with pVAX I.
Immunization and challenge
A total of 100 female Kunming mice were randomly di-
vided into four groups (25 per group). For the experi-
mental group, mice were immunized with 100 μl
(100 μg) pVAX-CDPK3 by intramuscular injections and
boosted with a two-week interval. Mice were injected
with empty pVAX I vector or PBS as negative control
groups, and the blank control group received nothing.
The sera of all groups were collected from the mouse
tail vein prior to each immunization and stored at −20°C
for ELISA. Pre-immune serum samples were used as
negative controls.
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Two weeks after the third inoculation, ten mice in all
groups were challenged intraperitoneally with 1 × 103
tachyzoites of the virulent T. gondii RH strain and the
survival time were recorded daily until all mice were
dead. Three mice of each group were inoculated orally
with 10 tissue cysts of the PRU strain and the brain cysts
were determined at four weeks after the challenge.
Expression and purification of TgCDPK3 protein in
bacteria
The obtained whole coding region was inserted into the
prokaryotic expression vector pET-30a, formed pET-
CDPK3, and then transformed into E. coli BL21 (DE3)
strain and grown in Luria Bertani (LB) with 25 μg/ml
kanamycin (Sangon, China). The expression of recom-
binant TgCDPK3 (rTgCDPK3) was under the condition
of 0.6 mM IPTG (Sangon, China) and shaking for 8 hour
at 35°C. The rTgCDPK3 protein was purified using Ni-
NTA His bind resin (Novagen) according to the manu-
facturer’s instructions. The products were visualized by
the sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE).
Immunoblotting analysis of the recombinant protein
The reactogenicity of rTgCDPK3 protein was then de-
tected by immunoblotting. Following SDS-PAGE,
rTgCDPK3 protein was electrotransferred onto nitrocel-
lulose (NC) membranes (Pall, USA). Nonspecific binding
sites were blocked with 5% bovine serum albumin (BSA)
in PBS for 1 h at room temperature (RT). The NC mem-
branes were then incubated with the sera of immunized
mice on week 6 (diluted in 1:1 000) for 1 h at RT. After
being washed 3 times with PBST (0.5% Tween 20 in
PBS), the membranes were incubated with diluted sec-
ondary antibody (goat anti-mouse IgG-HRP, Sigma,
USA; 1:5 000) for 1 h at RT. Proteins were visualized
with 4-chloro-1-naphthol (4-CN, Sangon, China) accord-
ing to the manufacture’ instruction. Sera collected before
vaccinations were used as negative control.
Antibody assays
rTgCDPK3-specific humoral immune response was eval-
uated by ELISA using SBA Clonotyping System-HRP Kit
(Southern Biotech CO., LTD, Birmingham, USA) accord-
ing to the manufacture’s instruction. A total of 100 μl
rTgCDPK3 (10 μg/ml) was coated on 96-well microtiter
plates at 4°C overnight. Mouse serum samples were
added to the wells and incubated at room temperature
for 1 h with gentle shaking. Then each well was incu-
bated with 100 μl of HRP conjugated anti-mouse IgG di-
luted in 1:250, anti-mouse IgG1 or IgG2a (1:500) for 1 h.
After added substrate solution (pH 4.0) (1.05% citrate
substrate buffer; 1.5% ABTS; 0.03% H2O2) for 20 min,
the absorbance was measured at 405 nm. All measure-
ments were performed in triplicate.
Lymphocyte proliferation assay by MTS
Two weeks after the last immunization, three mice per
group were euthanized, and their splenocytes were asep-
tically harvested through a wire mesh and then purified by
removing the red blood cells using RBC lysis solution
(Sigma, USA). The lymphocytes from each group were
then cultured in triplicate at a density of 2 × 105 cells
per well in complete medium (DMEM medium + 10%
FCS + 100 U/ml penicillin/streptomycin). The cells were
stimulated with TLA (10 μg/ml), concanavalin A (ConA;
5 μg/ml; Sigma) or medium alone served as positive and
negative controls respectively, at 37°C in a 5% CO2 incu-
bator. The proliferative activity was measured using MTS
method (Promega, USA) after four days. The stimulation
index (SI) was calculated by using the formula (OD570TLA/
OD570M): (OD570ConA/OD570M).
Flow cytometry
The T cell subclasses, CD4+ and CD8+ in spleen were
determined to the percentage using flow cytometry with
staining by phycoerythrin (PE)-labeled anti-mouse CD3
(eBioscience), Allophycocyanin (APC)-labeled anti-
mouse CD4 (eBioscience) and fluorescein isothiocyanate
(FITC)-labeled anti-mouse CD8 (eBioscience) antibodies.
After washing by PBS, the cells were fixed with FACScan
buffer (PBS containing 1% BSA and 0.1% Sodium azide)
and% paraformaldehyde. All the samples were analyzed
of fluorescence profiles on a FACScan flow cytometer
(BD Biosciences) using SYSTEM II software (Coulter).
Cytokine assays
The splenocytes without RBC from each group were co-
cultured with TLA for positive control and medium
alone for negative control in 96-well flat-bottom microti-
ter plates as described in the section of lymphocyte pro-
liferation assay. Culture supernatants were harvested at
24 h for determination of IL-2 and IL-4, 72 h for IL-10,
and 96 h for IL-23, IFN-γ and IL-12(p70) using commer-
cial ELISA kits according to the manufacturer’s instruc-
tions (Biolegend, USA). The analysis was performed with
the data from three independent experiments.
Statistical analysis
All statistical analyses were performed following the pro-
cedure of SAS (Statistical Analysis System, Version 8.0).
The differences of each variable including antibody re-
sponses, lymphoproliferation assays, cytokine produc-
tion, and percentages of CD4+ and CD8+ T cells among
all the groups were compared by one-way ANOVA. The
level of significant difference in comparisons between
groups was defined as P < 0.05.
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Results
Detection of the eukaryotic and prokaryotic expression of
TgCDPK3
The expression of pVAX-CDPK3 was identified using
IFA. As shown in Figure 1, specific green fluorescence
was observed in HEK293 cells transfected with the
eukaryotic recombinant plasmid pVAX-CDPK3, but not
in the negative controls that transfected with the same
amount of empty pVAX I. These results revealed that
the TgCDPK3 protein was expressed successfully in
HEK293 cells.
E. coli BL21 (DE3) transferred with pET-CDPK3 was
separated by SDS-PAGE. After staining by Coomassie
brilliant blue, the rTgCDPK3 protein was shown at the
position of approximately 70 kDa, which was consistent
with the theoretical value (Figure 2).
Western blotting and antibody responses
To determine the reactogenicity of rTgCDPK3 protein,
western blotting showed that the anti-CDPK3 antibody
could recognize the protein at the position of approxi-
mately 70 kDa. No band was found when the protein
reacted with the negative sera (Figure 2).
The levels of specific antibody response were mea-
sured by ELISA. As shown in Figure 3A, a higher level
of specific IgG antibodies was detected in those mice
immunized with pVAX-CDPK3 (P < 0.05), and the OD
values in pVAX-CDPK3 group reached to a significantly
high level with successive immunization (P < 0.05). In
contrast, antibodies in mice from three control groups
did not statistically increase with injection. In order
to characterize whether a Th1 and/or Th2 response
was elicited in immunized mice, the subclasses of IgG
(IgG1 and IgG2a) specific to rTgCDPK3 were analyzed
individually in sera from all groups at two weeks after
the last immunization. A mixed IgG1/IgG2a response
was determined in the sera of mice immunized with
pVAX-CDPK3 (Figure 3B), and OD values of IgG2a was
observed statistically higher than IgG1 (P < 0.05). All
these results indicated that both a specific humoral re-
sponse and the Th1 type immune response were elicited.
Evaluation of splenocyte proliferation
The proliferative response was observed after 96 h of
splenocytes co-cultured with stimulant. As shown in
Table 1, the proliferation SI from pVAX-CDPK3 vacci-
nated group (1.30 ± 0.18) was significantly increased
when compared with vaccination with PBS (0.91 ± 0.01),
pVAX I (0.89 ± 0.07) or blank control (0.97 ± 0.01).
Figure 1 Analysis of TgCDPK3 expression in HEK293 cells by indirect immunofluorescence (IFA) at 48 h post-transfection. (A) HEK293
cells were transfected with pVAX-CDPK3; (B) empty vector pVAX I.
Figure 2 Identification of CDPK3 expression in E. coli BL21
(DE3) by SDS-PAGE and western-blotting. M: protein molecular
weight marker; lane 1, recombinant pET-30a (+); lane 2, rTgCDPK3
induced for 8 h with 0.6 mmol/L IPTG; lane 3, Elution result of
20 mmol/L imidazole solution; lane 4, Elution result of 50 mmol/L
imidazole solution; lane 5, Western blotting analysis with the sera
against pVAX-CDPK3; lane 6, Western blotting analysis with the sera
before immunization.
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Percentages of CD4+ and CD8+ T lymphocyte
As shown in Table 1, the percentages of CD3+ CD4+ T
lymphocytes in pVAX-CDPK3 group (CD4+ with 20.33 ±
3.06) were higher than those in PBS group (CD4+ with
13.70 ± 2.41), in pVAX I group (CD4+ with 14.17 ± 1.88),
or in blank control (CD4+ with 15.27 ± 1.89) (P < 0.05).
The ratio of CD3+ CD8+ T cells in the spleen of vacci-
nated mice was slightly higher than that in all the controls,
but the difference was not statistically significant (P >
0.05). There was no difference in terms of the percentages
of CD3+ CD4+ and CD3+ CD8+ T lymphocytes among
the three control groups.
Cytokine production by spleen cells
Two weeks after the final immunization, spleen cell sus-
pensions from individual mice were stimulated in vitro
with TLA and were qualified with ELISA. As shown in
Table 2, a significantly high level of IFN-γ, IL-23, IL-12
(p70) and IL-2 was observed in spleen cell cultures from
mice immunized with pVAX-CDPK3 compared with
that in the pVAX I, PBS and the blank control groups
(P < 0.05). In the meanwhile, the levels of IL-4 and IL-10
were also slightly increased in supernatants from spleen
cells of mice immunized with pVAX-CDPK3 compared
to these control groups (P < 0.05).
Protective activity induced by vaccination with pVAX-CDPK3
To determine whether pVAX-CDPK3 can induce effect-
ive protection against T. gondii acute infection, 10 mice
from each group were intraperitoneally challenged with
a lethal dose of tachyzoites of the virulent T. gondii RH
strain two weeks after the last immunization. The aver-
age survival time of immunized mice was significantly
longer than that of the control groups (Figure 4).
Mice injected with pVAX I, PBS and blank control
did not reveal significant differences in their survival
time (P > 0.05).
To evaluate whether immune responses generated
against pVAX-CDPK3 were sufficient for providing pro-
tection against the formation of T. gondii tissue cysts in
the brain, all the groups of mice were challenged with 10
cysts of T. gondii PRU strain per mouse and the brain
cysts loads were assessed 30 days after challenge. As
shown in Table 3, mice immunized with pVAX-CDPK3
produced significantly fewer brain cysts than the control
groups (P < 0.05).
Discussion
T. gondii can infect all types of nucleated cells and
evolves several pathways to assure entry-exit from
the cells [17]. Plant-like CDPKs are considered to play
important signaling roles in the signal transduction
cascades. Among them, TgCDPK3 activity, which is
likely determined by calcium and potassium concentra-
tion, can control the calcium-dependent permeabilization
of the parasitophorous vacuole membrane (PVM) and
regulate microneme secretion and thus plays a vital role in
the rapid induction of parasite egress [15,18]. Considering
the crucial biological characteristics of TgCDPK3, we
Figure 3 Specific antibody response induced by DNA immunization with pVAX-CDPK3, pVAX I, PBS and blank controls using ELISA.
(A) Determination of specific anti-TgCDPK3 IgG antibodies in the sera of Kunming mice at 0, 2, 4, and 6 weeks. (B) Determination of the specific
anti-TgCDPK3 IgG subclass profile (IgG1 or IgG2a) in the sera of Kunming mice two weeks after the last immunization. Each bar represents the
mean OD (±S.E., n = 3). Statistically significant differences of OD values (P < 0.05) are indicated by (**).
Table 1 Splenocyte proliferative responses and the
percentages of T cell subsets in immunized mice 2 weeks
after the last immunization
Groups SI (Mean ± SD) CD3 + CD4 +
CD8− (%)
CD3 + CD8 +
CD4− (%)
pVAX-CDPK3 1.30 ± 0.18** 20.33 ± 3.06** 8.90 ± 2.95
pVAX I 0.89 ± 0.07 14.17 ± 1.88 6.47 ± 1.20
PBS 0.91 ± 0.01 13.70 ± 2.41 6.37 ± 1.25
Blank control 0.97 ± 0.01 15.27 ± 1.89 5.03 ± 0.40
SI stands for stimulation index.
**Statistically significant difference (P < 0.05).
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firstly studied the various immune responses elicited by
immunization with the DNA vaccine coding TgCDPK3
protein and evaluated its vaccinal potentiality.
In recent years, many studies have evaluated the pro-
tective immune responses elicited by different single an-
tigens including ADF, NTPase, IMP, ROM1, ROP18 and
elF4A [16,19-23], which showed partial protection
against T. gondii in mice model. In the present study,
vaccination of Kunming mice with pVAX-CDPK3 can
induce high levels of specific humoral and cellular im-
mune responses, resulting in effective protective immun-
ity, showing increased survival time (RH strain: 13.5 ±
4.89 days, P < 0.05) and reduced brain cysts (PRU strain:
50%, P < 0.05) contrasted with the control mice, which
demonstrated that TgCDPK3 is a promising DNA vac-
cine candidate against toxoplasmosis.
Specific antibody response has been considered to be
important in immunity against T. gondii. In the present
study, the mice immunized intramuscularly with pVAX-
CDPK3 produced specific antibodies against T. gondii
CDPK3, which may have the ability to kill the parasite
by the attachment of the parasite to the host cell recep-
tors, or the complement protein [24,25].
Due to the obligate intracellular lifestyle, T cell-
mediated adaptive immune responses involving in CD4+
and CD8+ Tcells are known to be important in resistance
against primary T. gondii infection and reactivation of
chronic toxoplasmosis [26-28]. In the present study, a
significantly proliferative response of splenocytes from
pVAX-CDPK3 vaccinated mice indicated that vigorous
cellular immune responses were induced by the DNA
vaccine. Furthermore, similar to the results from DNA
vaccination with ROP2, actin depolymerizing factor pro-
tein (ADP) and rhomboid protein (ROM1) of T. gondii
[29-31], the percentages of both CD4+ T cells were also
increased in pVAX-CDPK3 immunized mice, which
again stated an activated CD4+ Tcells immune response.
It is well established that the development of Th1-type
lymphocytes are considered to play a critical role in the
protective immunity against T. gondii [32-34]. So, the
present study further analyzed the CD4+ T cells with a
helper T cell type 1 (Th1) cytokine secretion profile and
antibodies subclass. Under our experimental conditions,
a mixed humoral response (IgG1/ IgG2a) with high ratio
of IgG2a to IgG1 antibody titers was observed in the
pVAX-CDPK3 vaccinated mice, and Th1 type response
correlative cytokines (IFN-γ, IL-2 and IL-12) released
from spleen cells of vaccinated mice were observed. The
low level increase of Th2 cytokines (IL-4 and IL-10)
Table 2 Cytokine production by splenocytes of immunized Kunming mice after stimulation by toxoplasma lysate
antigena
Groups Cytokine production (pg/ml)
IFN-γ IL-2 IL-4 IL-10 IL-12 (p70) IL-23
pVAX-CDPK3 612.11 ± 128.56** 263.79 ± 35.43** 32.42 ± 2.74** 870.12 ± 226.50** 129.63 ± 77.42** 87.59 ± 7.14**
pVAX I 34.91 ± 11.23 <15 <15 322.50 ± 179.17 15.14 ± 7.63 19.93 ± 22.65
PBS 36.34 ± 4.83 <15 18.96 356.13 ± 175.27 22.31 ± 4.40 27.12 ± 18.46
Blank control 47.28 ± 16.60 <15 <15 477.25 ± 87.53 22.65 ± 21.90 23.68 ± 14.13
aSplenocytes from mice were harvested two weeks after the last immunization.
**Statistically significant difference (P < 0.05).
Figure 4 Survival rate of mice immunized with pVAX-CDPK3,
pVAX I, PBS and nothing followed by challenge with 1 × 103
tachyzoites 2 weeks after the last immunization. The mice
immunized with pVAX-CDPK3 were dead from day 10 to 24 that
showed an increased survival time (13.5 ± 4.89 days) compared with
mice in the control groups (pVAX1, PBS, blanking controls) died
within 7 days after challenge (P < 0.05).
Table 3 Mean tissue cyst load in the brain of immunized
mice after challenge with 10 cysts of T. gondii PRU strain
Groups Number of brain cysts (Means ± SD)
pVAX I 3377.78 ± 226.08
PBS 3166.67 ± 258.77
Blank control 3232.78 ± 196.64
pVAX-CDPK3 1566.67 ± 167.10**
**Statistically significant difference (P < 0.05).
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induced by pVAX-CDPK3, which is also detected in the
mice immunized with eIF4A, MIC6 and PLP [19,35,36],
is likely because the antigen in the cytosol of antigen
presenting cells (APCs) was not only processed and pre-
sented by MHC Class I molecules but was also present by
MHC Class II molecules. These finding revealed that a
predominant Th1 type cell immune response has been
driven by immunization with pVAX-CDPK3.
Cytokines play an important role in immunity against
T. gondii infection by both stimulating macrophages and
CTL protective immunity during the innate and adaptive
immune response [37,38]. IL-4 and IL-10 can promote
the proliferation and differentiation of activated B cells,
mast cells and peripheral lymphocytes and were showed
to play an important role during the early phase of acute
T. gondii infection [39,40], which partially contributed to
protection against the acute stage of T. gondii infection
in the present study. IL-23 secreted by activated macro-
phages and dendritic cells has been shown to enhance
the production of the most critical cytokine, IFN-γ, in
mediating host protection against T. gondii infection.
IFN-γ, which was produced by T cells and NK cells, can
restrict the growth of T. gondii in the acute phase of the
infection and the reactivation of parasites from dormant
cysts through triggering lysosomal activity, inducing ni-
tric oxide production and modulating metabolic activity
of some antigen presenting cells [38,41,42]. Furthermore,
IFN-γ in combined with IL-2 and IL-12 is involved in
the protection against parasitic invasions [37]. Therefore,
our results of the high level of IFN-γ, IL-2, IL-12 (p70)
and IL-23 in the mice immunized with pVAX-CDPK3
suggested that these Th1-type cytokines confer host re-
sistance against T. gondii infection.
Conclusions
The present study evaluated, for the first time, the im-
munogenicity and protective potency of a DNA vaccine
encoding TgCDPK3, and demonstrated that TgCDPK3 is
a potential vaccine candidate against acute and chronic
toxoplasmosis in the mice model, and warrant further
studies in other apicomplexan parasites.
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